Business Wire

Hyperice Launches Normatec Elite Hips: Dynamic Air Compression Device that Eliminates Hoses and Separate Control Units

14.10.2025 15:00:00 CEST | Business Wire | Press Release

Share

Hyperice, a global high-performance wellness brand, today announced the launch of Normatec Elite Hips, the first-ever fully portable dynamic air compression device specifically engineered for the hips, IT bands, and lower back. This standalone device represents a new era of targeted recovery, eliminating the need for separate control units and delivering clinical-grade compression therapy with unprecedented portability and convenience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251014033083/en/

Normatec Elite Hips is the latest addition to the award-winning Normatec lineage. Hyperice reset the industry standard for dynamic air compression therapy with the introduction of Normatec Elite in June 2024, building on the success of the award-winning Normatec 3 line.

Normatec Elite Hips marks an evolution from attachment to an independent device in recovery offerings, transforming how athletes, fitness enthusiasts, and anyone seeking optimal movement can address hip tightness, IT band discomfort, lower back tension, and mobility restrictions. With a sleek, cordless design and gapless compression coverage, the device delivers next-level hip care. Whether caused by intense training, prolonged sitting, or the natural wear of daily activity, hip and lower back problems impact quality of life across all demographics. Normatec provides a science-backed solution that addresses these common challenges with the same technology trusted by professional sports leagues.

"The hips and lower back are the foundation for a lot of movement," said Jim Huether, CEO of Hyperice. “Normatec Elite Hips represents our commitment to making professional-grade recovery technology accessible to everyone. By creating the first standalone hip recovery device with true portability, we're empowering people to take control of their mobility and movement quality wherever they are."

Key Innovation Features:

  • Truly Portable Recovery: No cords, no setup, no limits. What was once an add-on product to traditional Normatec systems is now available as a standalone product. Normatec Elite Hips delivers clinical-grade compression therapy with up to 4 hours of battery life, enabling recovery at home, in the gym, and beyond. The device is TSA-friendly for travel convenience.
  • Seven Levels of Compression: Users can choose from seven intensities (40–110 mmHg) to match their specific needs – whether it's post-workout relief, lower back tension management, or targeted hip activation before activity.
  • Gapless Coverage: Two independent compression zones work together to provide seamless coverage across IT bands, thighs, hamstrings, hips, and lower back, ensuring no missed areas or uneven pressure distribution. Adjustable velcro straps around the leg ensure a secure fit, delivering consistent pressure and optimal results every session.
  • Bluetooth Connection: Bluetooth connectivity to the Hyperice App enables customized settings and personalized protocols.

Engineered for Complete Hip Wellness

Designed by a PhD and a physician bioengineer, the Normatec product line replicates the natural muscle pumps of the body, the one-way valves of the venous system, and peristalsis (cyclical waves of compression) to efficiently mobilize fluid to improve circulation, reduce swelling and inflammation, and accelerate recovery. The patented technology delivers targeted relief that helps users loosen tight hips and lower back, recover faster after workouts, improve range of motion and flexibility, and feel lighter, looser, and more mobile.

"From clinical environments to the locker room and beyond, Normatec has become synonymous with recovery," said Gilad Jacobs, Hyperice Chief Innovation Officer and Normatec Recovery Founder. "Normatec Elite Hips represents the next evolution of our technology – bringing targeted, professional-level hip recovery to anyone who needs it, in a form factor that fits seamlessly into daily life."

Clinical research supports the efficacy of dynamic air compression for recovery and mobility enhancement. A recent study comparing cryotherapy versus dynamic compression in low back pain patients found that while both treatments reduced pain, only dynamic compression improved range of motion across all measured parameters, with statistically significant improvements in lumbar flexion, hip flexion, and trunk mobility.

Normatec Elite Hips is the latest addition to the award-winning Normatec lineage. Hyperice reset the industry standard for dynamic air compression therapy with the introduction of Normatec Elite in June 2024, building on the success of the award-winning Normatec 3 line.

Normatec Elite Hips is available now for $599 USD and CA$799 at hyperice.com, Best Buy, Dick's Sporting Goods, and REI. The device is FSA/HSA eligible, making professional-grade recovery technology more accessible to consumers.

In Europe and the UK, the same cutting-edge technology will be available at hyperice.com as Normatec Premier Hips on November 10, for 599€ and £529.

About Hyperice

Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), contrast therapy (Hyperice X), and Hyperboot collaboration with Nike. Now, as a holistic high-performance wellness brand, Hyperice is designed for all – from the most elite athletes, leagues, and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies and a TIME Best Inventions winner, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance, and workplace wellness on a global scale. For more information, visit hyperice.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251014033083/en/

Contacts

Jack Taylor PR
hyperice@jacktaylorpr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting Strengthens Digital Transformation Capabilities with Weexa30.4.2026 15:30:00 CEST | Press Release

Andersen Consulting enters into a Collaboration Agreement with Weexa, a global provider of digital transformation, B2B integration, and supply chain digitalization solutions. Headquartered in France, Weexa delivers end-to-end services that help organizations streamline, secure, and scale their digital ecosystems. The firm specializes in B2B data-flow management and digitalization, enabling seamless communication between applications both within and across organizations through technologies such as EDI, APIs, and e-invoicing. Weexa also provides SAP integration and supply chain solutions spanning warehouse and transport management, alongside strategic consulting, project delivery, and third-party application maintenance. Serving organizations across the food, retail, wholesale, logistics, transportation, automotive, healthcare, and media sectors, Weexa supports global businesses in optimizing performance while meeting evolving regulatory and digital-compliance requirements. “Collaborati

SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 15:22:00 CEST | Press Release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et

Experian Announces Agent Trust to Power Trusted AI Driven Commerce30.4.2026 15:00:00 CEST | Press Release

Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430719198/en/ Experian Announces Agent Trust to Power Trusted AI Driven Commerce. As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust addresses this challenge through a new “Know Your Agent” (KYA) framework, extending identity verification into the age of AI. The framework ensures that agent-initiated transactions are grounded in verified consumer identity. “Agen

Meet the AI-powered fan companion: TGR Haas F1 Team RaceMate powered by Infobip30.4.2026 15:00:00 CEST | Press Release

Global AI-first cloud communications platform Infobip and TGR Haas F1 team are launching ‘TGR Haas F1 Team RaceMate powered by Infobip’, an AI-powered conversational fan companion on Apple Messages for Business and WhatsApp Business Platform. Always-on and always available, it delivers race intelligence for TGR Haas F1 Team: team race intelligence, grid positions, qualifying outcomes, sprint results, and full session schedules. The AI agent tracks drivers Ollie Bearman and Esteban Ocon with their individual championship standings and performance data in conversational format. The agent draws from a knowledge base covering driver biographies, team history, and circuit data, adapting to each user's knowledge level. Every interaction begins with a schedule check, ensuring fans always know what's happening right now. It proactively surfaces relevant information, suggests next actions, and maintains conversational flow to keep every interaction effortless and engaging. Delivered in short, s

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press Release

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye